AU2001296477A1 - Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas - Google Patents

Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas

Info

Publication number
AU2001296477A1
AU2001296477A1 AU2001296477A AU9647701A AU2001296477A1 AU 2001296477 A1 AU2001296477 A1 AU 2001296477A1 AU 2001296477 A AU2001296477 A AU 2001296477A AU 9647701 A AU9647701 A AU 9647701A AU 2001296477 A1 AU2001296477 A1 AU 2001296477A1
Authority
AU
Australia
Prior art keywords
cyr61
diagnosis
treatment
human uterine
uterine leiomyomas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296477A
Inventor
Deepak Sampath
Richard Winneker
Zhiming Zhang
Yuan Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of AU2001296477A1 publication Critical patent/AU2001296477A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
AU2001296477A 2000-09-29 2001-09-28 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas Abandoned AU2001296477A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23688700P 2000-09-29 2000-09-29
US60/236,887 2000-09-29
PCT/US2001/030783 WO2002026193A2 (en) 2000-09-29 2001-09-28 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas

Publications (1)

Publication Number Publication Date
AU2001296477A1 true AU2001296477A1 (en) 2002-04-08

Family

ID=22891403

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001296477A Abandoned AU2001296477A1 (en) 2000-09-29 2001-09-28 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas

Country Status (5)

Country Link
EP (1) EP1322778A4 (en)
JP (1) JP2004509909A (en)
AU (1) AU2001296477A1 (en)
CA (1) CA2423413A1 (en)
WO (1) WO2002026193A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858324B2 (en) * 2005-02-18 2010-12-28 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
TW201102086A (en) 2009-06-04 2011-01-16 Hoffmann La Roche Antibodies against human CCN1 and uses thereof
EP2540742A4 (en) * 2009-12-04 2014-02-12 Shanghai Inst Of Immunology Anti-cyr61 protein monoclonal antibodies and uses thereof
EP3364190A1 (en) * 2017-02-20 2018-08-22 Panka Cancer Research AG Method of detecting cancer or cancer cells
CN108752454B (en) * 2018-06-19 2021-07-20 中山大学孙逸仙纪念医院 Human CYR61 protein Ser188 site phosphorylation antigen and antibody, and preparation method and application thereof
RU2704817C1 (en) * 2019-07-09 2019-10-31 Федеральное государственное бюджетное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения Российской Федерации Method for predicting uterine leiomyoma size increase

Also Published As

Publication number Publication date
CA2423413A1 (en) 2002-04-04
WO2002026193A2 (en) 2002-04-04
EP1322778A4 (en) 2005-06-15
WO2002026193A9 (en) 2003-02-20
JP2004509909A (en) 2004-04-02
EP1322778A2 (en) 2003-07-02
WO2002026193A3 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
AU2001275177A1 (en) Cardiac disease treatment and device
AU2001253565A1 (en) Cardiac disease treatment and device
AU2001275176A1 (en) Cardiac disease treatment and device
AU2001281369A1 (en) Cardiac disease treatment and device
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
AU1166502A (en) Human ect2 and methods of use
IL205242A0 (en) Substituted oxazolidinones and their use in the field of blood coagulation
AU2001249835A1 (en) Diagnosis and treatment of alzheimer's disease
AU2003243551A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
AU2002227184A1 (en) Methods for development and use of diagnostic and therapeutic agents
AU2001280440A1 (en) Treatment of human herpesviruses using hyperthermia
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
AU2002222108A1 (en) Diagnosis and treatment of alzheimer's disease
AU2002220257A1 (en) Methods of treatment involving human mda-7
AU2003238242A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
AU2001296477A1 (en) Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
AU3501700A (en) Human endokine alpha and methods of use
AU2001253886A1 (en) Methylxanthines in the diagnosis and treatment of autistic disorder
AU2001242490A1 (en) Device for treating human and/or animal tissue
AU4319001A (en) Microcompetiton and human disease
GB9908059D0 (en) Diagnosis and treatment of diseases
AU2001253024A1 (en) Diagnosis and treatment of gastrointestinal disease
AU2001285026A1 (en) Methods and compositions for use in the diagnosis and treatment of chronic immune disease